General Information

Government Type

State Agency

Entity

Department of Health and Human Services (DHHS)

Public Body

Pharmacy and Therapeutics Committee

Notice Information

Add Notice to Calendar

Notice Title

State Medicaid Pharmacy & Therapeutics Committee Meeting

Notice Tags

Medicaid, Pharmacies

Notice Type(s)

Meeting

Event Start Date & Time

May 16, 2013 07:00 AM

Event End Date & Time

May 16, 2013 08:30 AM

Event Deadline Date & Time

05/09/13 06:00 PM

Description/Agenda

UTAH DEPARTMENT OF HEALTH STATE MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE Thursday, May 16, 2013 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 128 (NOTE: Room Change) AGENDA Please note that persons who wish to address the P&T Committee may contact Lisa V. Hunt (lvhunt@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints 1) Welcome and Introductions...................................................................................................Kort Delost, R.Ph. a) Review and Approval of Minutes 2) Update on PDL Administration…………......................................................................Lisa V. Hunt, R.Ph. a) Housekeeping. 3) DUR Board Update.........................................................................................................Robyn Seely, PharmD. 4) Factor Xa Inhibitors Clinical Outcomes…………………………………………..Melissa Archer, PharmD. Agents to include: Apixaban (Eliquis), Fondaparinux (Arixtra), Rivaroxaban (Xarelto) a. Other States Report…………………………………………………………………... Lisa V. Hunt, R.Ph. b. Public Comment: i) Lori Blackner, Pharm D; Medical Outcomes Specialist (MOS) Pfizer Global Medical c. Board Discussion/Questions d. Board Action 5) Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Clinical Outcomes…………..Melissa Archer, PharmD. Agents to include: Exenatide (Byetta®), Liraglutide (Victoza®) a. Other States Report…………………………………………………………………... Lisa V. Hunt, R.Ph. b. Public Comment c. Board Discussion/Questions d. Board Action 6) Next Meeting July 18, 2013, Sulfonylurea Drug Class Review 7) Meeting Adjourned………………………………………………………..........Chair, Ellie Brownstein, M.D. Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to: Dr. Gary Oderda College of Pharmacy 30 South 2000 East SLC, UT 84112-5820 All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search. Tentative Medicaid P&T Schedule 2013 Month Topic Agents 06/20/13 Meeting cancelled due to annual bid review N/A 07/18/13 Sulfonylurea Drug Class Review Chlorpropamide (Diabinese), Glimepiride (Amaryl), Glipizide (Glucotrol), Glyburide (Micronase®), Tolazamide (Tolinase®), Tolbutamide (Orinase) Sulfonylurea Combination Products Drug Class Review Metformin/Glipizide (Metaglip), Metformin/Glyburide (Glucovance) 08/15/13 Thiazolidinedione Drug Class Review Pioglitazone (Actos), Rosiglitazone (Avandia) Thiazolidindione Combination Products Drug Class Review Metformin/Pioglitazone (Actoplus Met), Metformin/Rosiglitazone (Avandamet 09/19/13 Phosphate Binding Agents Drug Class Review Calcium Acetate (Eliphos™; PhosLo®; Phoslyra™), Lanthanum (Fosrenol®), Sevelamer (Renagel®) 10/17/13 Topical Immune-modulators Drug Class Review Pimecrolimus (Elidel®); Tacrolimus (Protopic®) 11/21/13 Topical/Local Anesthetic Agents Drug Class Review Articaine, Benzocaine, Benzydamine, Benzyl Alcohol, Bupivacaine, Capsaicin, Cetylpyridinium, Chloroprocaine, Dibucaine, Dyclonine, Ethyl Chloride, Hexylresorcinol, Lidocaine, Mepivacaine, Pramoxine, Prilocaine, Proparacaine, Ropivacaine, Tetracaine, Trolamine, Zucapsaicin 12/19/13 Pediculoside Agents Drug Class Review Benzyl Alcohol, Ivermectin, Lindane, Malathion, Permethrin, Pyrethrins and Piperonyl Butoxide, Spinosad 01/16/14 Long Acting Opioid Agents Long-acting Class Update 02/20/14 Short Acting Opioid Agents Short-acting Agents 03/20/14 Immediate Acting Opioid Agents Immediate-acting Agents

Notice of Special Accommodations (ADA)

NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Lisa Hunt at 801-538-6317.

Notice of Electronic or Telephone Participation

NOTICE OF POSSIBLE ELECTRONIC OR TELEPHONIC PARTICIPATION One or more members of the Pharmacy & Therapeutics Committee may participate electronically or telephonically pursuant to UCA 52-4-7.8

Meeting Information

Meeting Location

288 North 1460 West
Cannon Health Building, Room 128
Salt Lake City, 84116
Show in Apple Maps Show in Google Maps

Contact Name

Ngan Huynh

Contact Email

nganhuynh@utah.gov

Contact Phone

801-538-6155

Notice Posting Details

Notice Posted On

April 23, 2013 08:27 AM

Notice Last Edited On

April 23, 2013 08:40 AM

Deadline Date

May 9, 2013 06:00 PM

Subscribe by Email

Subscription options will send you alerts regarding future notices posted by this Body.